Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Hepatology. 2012 Oct 14;56(5):1602–1610. doi: 10.1002/hep.25821

Fig. 6. Rituximab restores the T1/T2-ratio in MC patients.

Fig. 6

HCV-infected patients with MC were studied prior to, during and after treatment with Rituximab for changes in HCV titer and percentage of B-cells (A), the kinetics of cryoglobulin and RF levels (B), the percentage of immature transitional B-cells within CD19+ B-cells (C), the percentage of T1 and T2 immature transitional B-cells (D), Ki-67 levels in T1 and T2 immature transitional B-cells (E), and the correlation of Ki-67 MFI of T2 immature transitional B-cells with the percentage of cryoglobulins (F). Mean±SEM are shown (n=9 patients). *p<0.05, **p<0.01, ***p<0.001 compared to pretreatment.